To determine the effects of VEGF-A/VEGFR2 signaling on medulloblastoma, we selected the well-documented VEGFR2 inhibitor SU5416 [22, 49] and the well-documented NAB [50, 51] to manipulate the activity of this pathway in medulloblastoma cells. The gene discussed is KDR; the disease is medulloblastoma.